PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

15 Nov 2017

• By Emily Hayes

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

The third quarter marked a turning point for Merck & Co. Inc.'s PD-1 inhibitor Keytruda, which hit the $1bn sales mark and finally started closing in on Bristol-Myers Squibb Co.'s market-leading competitor Opdivo, but with many catalysts around the corner for the most valuable indication of lung cancer, investors are bracing for shakeups.

Opdivo's performance in the third quarter was better than expected as nivolumab brought in $1.3bn in sales, up by 38%...